Scarica l'app Stockscreener
2.81
0.36%
0.01
Dopo l'orario di chiusura:
2.91
0.10
+3.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Mei Pharma Inc Borsa (MEIP) Ultime notizie
MEI Pharma Reports Strategic Shift Amid Financial Losses - TipRanks
MEI Pharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
MEI Pharma reports Q1 EPS ($1.20) vs. $8.46 last year - TipRanks
Acute Myeloid Leukemia (AML) Treatment Market in APAC to Grow by USD 305.8 Million from 2024-2028, Driven by High Incidence and AI-Driven Market TransformationTechnavio - Chicago Star Media
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Data Readouts At EHA Congress 2021 (APTO, XFOR, GBT, CRIS…) - RTTNews
Stocks to Watch: MEI Pharma, Hawaiian Electric Industries - MarketWatch
MEI Shares Rise After Entering Asset Purchase Agreement Valued at Up to $62 Million - MarketWatch
MEI Pharma postpones special meeting to vote on Infinity deal until July 23 - MSN
Aardvark Therapeutics, Inc. agreed to acquire rights, title and interest in and to certain assets related to ME-344 from MEI Pharma, Inc. for $62.5 million. - Marketscreener.com
MEIP (MEI Pharma) Free Cash Flow per Share : $-7.57 (TTM As of Jun. 2024) - GuruFocus.com
Post Polycythemia Vera Myelofibrosis Market: Holistic - openPR
Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated by Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.72 amid market challenges - Investing.com India
MEI Pharma stock hits 52-week low at $2.72 amid market challenges By Investing.com - Investing.com South Africa
Acute Myeloid Leukemia Market Trends, Key Drivers, Opportunities, Leading Players And Forecast To 2033 - WhaTech
Histone Deacetylase 2 Industry Forecast (2024-2034) Under Inflation - Apiculture Market: Report ...
Myelodysplastic Syndrome Drugs Market Research Explores Size, Market Competitive Landscape, Business Growth... - WhaTech
Chronic Lymphocytic Leukemia Treatment Market Advancements Highlighted by Comprehensive Analysis, Advanceme... - WhaTech
Follicular Lymphoma Treatment Market Insights Discussed Regarding Size, Trends, and Overview Report 2024-2033 - WhaTech
MEI Pharma reviews strategic options amid fiscal changes - Investing.com India
MEI Pharma confirms continuation of evaluation of strategic alternatives - TipRanks
MEI Pharma Reports Fiscal Year End 2024 Cash Position - The Bakersfield Californian
Expanding the Bispecific Antibody Market from CAR-Ts to Drive Follicular Lymphoma's Future | DelveInsight - PR Newswire UK
LPL Financial (NASDAQ:LPLA) Research Coverage Started at Wells Fargo & Company - Defense World
Los Angeles Capital Management LLC Reduces Stake in Martin Marietta Materials, Inc. (NYSE:MLM) - Defense World
Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib - Reuters.com
Histone Deacetylase Inhibitors Report 2024, Industry Analysis And Overview By 2033 - WhaTech
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry - openPR
MEIP (MEI Pharma) Dividends per Share : $0.00 (TTM As of Mar. 2024) - GuruFocus.com
Rx Rundown: Vantive, Gilead Sciences, Halda Therapeutics and more - MM+M Online
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives - StockTitan
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
GreenWood Investors First Half 2024 Letter - Seeking Alpha
MEI Pharma (MEIP) – Research Analysts’ Recent Ratings Updates - Defense World
Game-Changing BCL-2 Inhibitors Set to Revolutionize Cancer Treatment Market | DelveInsight - GlobeNewswire
MEI Pharma announces executive departures and strategic shifts - Investing.com
MEI Pharma announces executive departures and strategic shifts By Investing.com - Investing.com Canada
MEI Pharma Explores Strategic Shifts, Leadership Changes - TipRanks
Non-Hodgkin's Lymphoma Therapeutics Market to Reach USD 18.6 Billion by 2034: Fuelled by New Drugs and Targeted Therapies | Latest Report by TMR - PR Newswire
MEI Pharma Explores Strategic Options, Halts Drug Development - TipRanks
Acadian Asset Management LLC Sells 13,658 Shares of MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World
Biopharma Layoff Tracker 2024: Anokion, GlycoMimetics, Relay and More Cut Staff - BioSpace
MEI Pharma (NASDAQ:MEIP) Receives New Coverage from Analysts at StockNews.com - Defense World
StockNews.com Initiates Coverage on Perficient (NASDAQ:PRFT) - Defense World
MEI Pharma (NASDAQ:MEIP) Downgraded by Brookline Capital Management - Defense World
State Board of Administration of Florida Retirement System Increases Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Blair William & Co. IL Takes Position in BRC Inc. (NYSE:BRCC) - Defense World
Avantax Advisory Services Inc. Buys Shares of 8,840 Dimensional World ex U.S. Core Equity 2 ETF (NYSEARCA:DFAX) - Defense World
MEI Pharma (NASDAQ:MEIP) Downgraded by Laidlaw - Defense World
Does MEI Pharma Inc (NASDAQ: MEIP) Still Need To Convince Analysts? - Stocks Register
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1 - Marketscreener.com
MEI Pharma stock downgraded amid strategic review and shutdown risk By Investing.com - Investing.com Canada
MEI Pharma initiates strategic review and layoffs By Investing.com - Investing.com Australia
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):